At Media Center

You Can Access Our Press Releases

Hepalink’s Enoxaparin Sodium Injection Approved in Macao SAR, Expanding Global Access Footprint to 82 Countries and Regions

(Shenzhen, November 17, 2026) Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink” or the “Group”) recently announced that all five strengths of enoxaparin sodium injection produced by its wholly-owned subsidiary Shenzhen Techdow Pharmaceutical Co., Ltd. (“Techdow”), the core entity undertaking the Group’s enoxaparin sodium API and formulation businesses, have received approval from the Pharmaceutical Administration Bureau (ISAF) of the Macao Special Administrative Region. With these approvals, Hepalink’s enoxaparin sodium injection has now been approved in 82 countries and regions worldwide, further expanding the global market access footprint of the Group’s core formulation product.



The product approved in Macao covers five strengths: 0.2 mL: 2,000 AXaIU, 0.4 mL: 4,000 AXaIU, 0.6 mL: 6,000 AXaIU, 0.8 mL: 8,000 AXaIU, and 1.0 mL: 10,000 AXaIU. Enoxaparin sodium is a low-molecular-weight heparin anticoagulant widely used in clinical practice and plays an important role in the prevention and treatment of thromboembolic diseases. The approvals will help address different dosage needs in local anticoagulation therapy, provide healthcare institutions and patients in Macao with a broader range of treatment options, and lay a foundation for the product’s subsequent commercialization in the market.


As a core product of Hepalink’s global formulations business, enoxaparin sodium injection, marketed under the Inhixa®/Neoparin® brands, became the first enoxaparin sodium biosimilar to receive marketing authorization from the European Medicines Agency (EMA) in 2016. Since then, the product has successively entered key markets including the United States, the European Union, the United Kingdom, Switzerland, Brazil, Argentina, Thailand, Singapore, and South Africa. It is currently sold in more than 50 countries and regions worldwide, supported by extensive experience in international registration and market operations.


Hepalink’s continued global expansion is underpinned by its vertically integrated value chain spanning heparin sodium API, enoxaparin sodium API, and finished formulations, together with its continuously advancing international quality management and advanced manufacturing systems. In recent years, Hepalink has been recognized as a Shenzhen Advanced-Level Smart Factory, included in the Ministry of Industry and Information Technology’s 2025 5G Factory Directory, and named a 2026 Shenzhen Green Factory, reflecting continued recognition of the Group’s intelligent and green manufacturing capabilities.


In 2026, the Hepalink Pingshan New Pre-filled Syringe Manufacturing Facility Project received the ISPE Facility of the Year Award (FOYA) in the “Innovation – Novel Technology” category, becoming the first pharmaceutical manufacturing facility project in mainland China to receive this award since the FOYA program was established more than two decades ago. With a designed annual production capacity of 330 million pre-filled syringes, the facility has obtained EU GMP certification and integrates advanced technologies including 5G, AI-enabled visual inspection, and zero-touch logistics. These capabilities further enhance quality control, operational efficiency, and large-scale supply of finished formulations, providing robust support for the Group’s reliable delivery of high-quality products to global markets.


Looking ahead, Hepalink will continue to deepen its global market presence and local partnerships, leveraging the synergies of its vertically integrated value chain, advanced manufacturing capabilities, and global supply chain to further improve access to high-quality anticoagulant therapies and benefit more patients worldwide.


About Hepalink’s Enoxaparin Sodium Injection


The Enoxaparin Sodium Injection produced by Hepalink’s wholly-owned subsidiary Techdow was the first enoxaparin sodium injection biosimilar to receive marketing authorization from the European Medicines Agency (EMA), and the first generic version of enoxaparin sodium injection to have all its marketed strengths pass China’s generic drug consistency evaluation. The product has now been approved in 82 countries and regions worldwide and is sold in more than 50 countries and regions globally. It is marketed under the brand name 普洛静® in China, Inhixa® in the EU (excluding Poland), Neoparin® in Poland, and Prolongin®/Inhixa® or other local brands in emerging markets.